Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 866

1.

Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era.

Hellesnes R, Kvammen Ø, Myklebust TÅ, Bremnes RM, Karlsdottir Á, Negaard HFS, Tandstad T, Wilsgaard T, Fosså SD, Haugnes HS.

Int J Cancer. 2019 Oct 9. doi: 10.1002/ijc.32704. [Epub ahead of print]

PMID:
31597192
2.

Extent of disease at first cancer presentation and previous anxiety and depressive symptoms: the HUNT study.

Stewart R, Fosså SD, Hotopf M, Mykletun A.

Br J Psychiatry. 2019 Oct 7:1-7. doi: 10.1192/bjp.2019.211. [Epub ahead of print]

PMID:
31587671
3.

Impact of positive surgical margins on secondary treatment, palliative radiotherapy and prostate cancer-specific mortality. A population-based study of 13 198 patients.

Kvåle R, Myklebust TÅ, Fosså SD, Aas K, Ekanger C, Helle SI, Honoré A, Møller B.

Prostate. 2019 Sep 30. doi: 10.1002/pros.23911. [Epub ahead of print]

PMID:
31566779
4.

Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy.

Trendowski MR, El-Charif O, Ratain MJ, Monahan P, Mu Z, Wheeler HE, Dinh PC Jr, Feldman DR, Ardeshir-Rouhani-Fard S, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Mushiroda T, Kubo M, Hannigan R, Strathmann F, Einhorn LH, Fossa SD, Travis LB, Dolan ME.

Clin Cancer Res. 2019 Oct 1;25(19):5913-5924. doi: 10.1158/1078-0432.CCR-19-0113. Epub 2019 Jul 11.

PMID:
31296530
5.

Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.

Abu Zaid M, Dinh PC, Monahan PO, Fung C, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Sesso HD, Huddart R, Mushiroda T, Kubo M, Dolan ME, Einhorn LH, Fossa SD, Travis LB; Platinum Study Group.

J Natl Compr Canc Netw. 2019 May 1;17(5):459-468. doi: 10.6004/jnccn.2018.7109.

PMID:
31085753
6.

Limited evidence of non-response bias despite modest response rate in a nationwide survey of long-term cancer survivors-results from the NOR-CAYACS study.

Lie HC, Rueegg CS, Fosså SD, Loge JH, Ruud E, Kiserud CE.

J Cancer Surviv. 2019 Jun;13(3):353-363. doi: 10.1007/s11764-019-00757-x. Epub 2019 Apr 16.

PMID:
30993649
7.

Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms.

El Charif O, Mapes B, Trendowski MR, Wheeler HE, Wing C, Dinh PC Jr, Frisina RD, Feldman DR, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Mushiroda T, Kubo M, Gamazon ER, Cox NJ, Huddart R, Ardeshir-Rouhani-Fard S, Monahan P, Fossa SD, Einhorn LH, Travis LB, Dolan ME.

Clin Cancer Res. 2019 Jul 1;25(13):4104-4116. doi: 10.1158/1078-0432.CCR-18-3179. Epub 2019 Apr 5.

PMID:
30952644
8.

Employment Status and Work Ability in Long-Term Young Adult Cancer Survivors.

Dahl AA, Fosså SD, Lie HC, Loge JH, Reinertsen KV, Ruud E, Kiserud CE.

J Adolesc Young Adult Oncol. 2019 Jun;8(3):304-311. doi: 10.1089/jayao.2018.0109. Epub 2019 Mar 22.

PMID:
30900929
9.

Changes in fatigue, health-related quality of life and physical activity after a one-week educational program for cancer survivors.

Gjerset GM, Kiserud CE, Loge JH, Fosså SD, Wisløff T, Gudbergsson SB, Oldervoll LM, Thorsen L.

Acta Oncol. 2019 May;58(5):682-689. doi: 10.1080/0284186X.2018.1562210. Epub 2019 Mar 12.

PMID:
30862228
10.

Chronic fatigue and associated factors among long-term survivors of cancers in young adulthood.

Bøhn SH, Thorsen L, Kiserud CE, Fosså SD, Lie HC, Loge JH, Wisløff T, Haugnes HS, Reinertsen KV.

Acta Oncol. 2019 May;58(5):753-762. doi: 10.1080/0284186X.2018.1557344. Epub 2019 Jan 30.

PMID:
30696351
11.

Is time from diagnosis to radical prostatectomy associated with oncological outcomes?

Aas K, Fosså SD, Kvåle R, Møller B, Myklebust TÅ, Vlatkovic L, Müller S, Berge V.

World J Urol. 2019 Aug;37(8):1571-1580. doi: 10.1007/s00345-018-2570-6. Epub 2018 Nov 27.

PMID:
30483947
12.

Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.

Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W.

Radiother Oncol. 2019 Mar;132:211-217. doi: 10.1016/j.radonc.2018.10.013. Epub 2018 Oct 30.

PMID:
30389241
13.

Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor.

Solheim O, Skalleberg J, Warncke T, Ørstavik K, Tropé C, Fosså SD.

Acta Obstet Gynecol Scand. 2019 Feb;98(2):240-249. doi: 10.1111/aogs.13477. Epub 2018 Nov 22.

PMID:
30289161
14.

Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol.

van der Kooi ALF, Clemens E, Broer L, Zolk O, Byrne J, Campbell H, van den Berg M, Berger C, Calaminus G, Dirksen U, Winther JF, Fosså SD, Grabow D, Haupt R, Kaiser M, Kepak T, Kremer L, Kruseova J, Modan-Moses D, Ranft A, Spix C, Kaatsch P, Laven JSE, van Dulmen-den Broeder E, Uitterlinden AG, van den Heuvel-Eibrink MM; PanCareLIFE Consortium.

BMC Cancer. 2018 Sep 26;18(1):930. doi: 10.1186/s12885-018-4834-3.

15.

Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE).

van den Berg M, van Dijk M, Byrne J, Campbell H, Berger C, Borgmann-Staudt A, Calaminus G, Dirksen U, Winther JF, Fossa SD, Grabow D, Grandage VL, van den Heuvel-Eibrink MM, Kaiser M, Kepak T, Kremer LC, Kruseova J, Kuehni CE, Lambalk CB, van Leeuwen FE, Leiper A, Modan-Moses D, Morsellino V, Spix C, Kaatsch P, van Dulmen-den Broeder E; PanCareLIFE Consortium.

JMIR Res Protoc. 2018 Sep 14;7(9):e10824. doi: 10.2196/10824.

16.

Physical activity and associations with treatment-induced adverse effects among prostate cancer patients.

Bøhn SH, Fosså SD, Wisløff T, Thorsen L.

Support Care Cancer. 2019 Mar;27(3):1001-1011. doi: 10.1007/s00520-018-4389-5. Epub 2018 Aug 9.

PMID:
30094728
17.

Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors.

Hjelle LV, Gundersen POM, Hellesnes R, Sprauten M, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Oldenburg J, Bremnes RM, Haugnes HS.

Acta Oncol. 2018 Oct;57(10):1392-1400. doi: 10.1080/0284186X.2018.1473641. Epub 2018 May 18.

PMID:
29775128
18.

Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors.

Fung C, Dinh P Jr, Ardeshir-Rouhani-Fard S, Schaffer K, Fossa SD, Travis LB.

Adv Urol. 2018 Feb 18;2018:8671832. doi: 10.1155/2018/8671832. eCollection 2018. Review.

19.

Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, Stump TE, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard C, Huddart RA, Kim J, Kollmannsberger C, Sahasrabudhe DM, Cook R, Fossa SD, Einhorn LH, Travis LB; Platinum Study Group.

J Clin Oncol. 2018 May 20;36(15):1505-1512. doi: 10.1200/JCO.2017.77.0735. Epub 2018 Apr 4.

20.

Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score.

Feldman DR, Ardeshir-Rouhani-Fard S, Monahan P, Sesso HD, Fung C, Williams AM, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Zaid MA, Lipshultz SE, Einhorn LH, Oeffinger KC, Travis LB, Fossa SD; Platinum Study Group.

Clin Genitourin Cancer. 2018 Aug;16(4):e761-e769. doi: 10.1016/j.clgc.2018.01.011. Epub 2018 Feb 5.

21.

Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors.

Zaid MA, Gathirua-Mwangi WG, Fung C, Monahan PO, El-Charif O, Williams AM, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse SK, Ardeshir-Rouhani-Fard S, Dinh PC, Sesso HD, Einhorn LH, Fossa SD, Travis LB; Platinum Study Group.

J Natl Compr Canc Netw. 2018 Mar;16(3):257-265. doi: 10.6004/jnccn.2017.7046.

22.

Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.

Haugnes HS, Stenklev NC, Brydøy M, Dahl O, Wilsgaard T, Laukli E, Fosså SD.

Acta Oncol. 2018 Aug;57(8):1075-1083. doi: 10.1080/0284186X.2018.1433323. Epub 2018 Jan 31.

PMID:
29384420
23.

Lowered reference limits for hCG improve follow-up of patients with hCG-producing tumors.

Nome RV, Bjøro T, Paus E, Bjerner J, Fosså SD, Steen R, Nustad K, Bolstad N.

Clin Biochem. 2018 Feb;52:73-79. doi: 10.1016/j.clinbiochem.2017.11.016. Epub 2017 Dec 2.

24.

Psychometric properties of the expanded prostate cancer index composite - 26 instrument in a cohort of radical prostatectomy patients: theoretical and practical examinations.

Axcrona K, Nilsson R, Brennhovd B, Sørebø Ø, Fosså SD, Dahl AA.

BMC Urol. 2017 Dec 2;17(1):111. doi: 10.1186/s12894-017-0302-7.

25.

Genetic factors influencing prostate cancer risk in Norwegian men.

Chen H, Ewing CM, Zheng S, Grindedaal EM, Cooney KA, Wiley K, Djurovic S, Andreassen OA, Axcrona K, Mills IG, Xu J, Maehle L, Fosså SD, Isaacs WB.

Prostate. 2018 Feb;78(3):186-192. doi: 10.1002/pros.23453. Epub 2017 Nov 27.

PMID:
29181843
26.

Correction to: Norwegian reference values for the Short-Form Health Survey 36: development over time.

Jacobsen EL, Bye A, Aass N, Fosså SD, Grotmol KS, Kaasa S, Loge JH, Moum T, Hjermstad MJ.

Qual Life Res. 2018 May;27(5):1213-1215. doi: 10.1007/s11136-017-1708-0.

27.

Cancer Survivorship in Adults.

Kiserud CE, Dahl AA, Fosså SD.

Recent Results Cancer Res. 2018;210:123-143. doi: 10.1007/978-3-319-64310-6_8.

PMID:
28924683
28.

Adverse Health Outcomes and Associations with Self-Reported General Health in Childhood Lymphoma Survivors.

Johannsdottir IMR, Hamre H, Fosså SD, Loge JH, Drolsum L, Lund MB, Nordsletten L, Kiserud C.

J Adolesc Young Adult Oncol. 2017 Sep;6(3):470-476. doi: 10.1089/jayao.2017.0018. Epub 2017 Aug 24.

PMID:
28837384
29.

H.V. Holm og medarbeidere svarer.

Holm HV, Dahl AA, Klepp OH, Fosså SD.

Tidsskr Nor Laegeforen. 2017 Aug 21;137(14-15). doi: 10.4045/tidsskr.17.0579. Print 2017 Aug 22. Norwegian. No abstract available.

PMID:
28828789
Free Article
30.

Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway.

Aas K, Axcrona K, Kvåle R, Møller B, Myklebust TÅ, Axcrona U, Berge V, Fosså SD.

Urology. 2017 Dec;110:140-147. doi: 10.1016/j.urology.2017.07.048. Epub 2017 Aug 18.

PMID:
28823634
31.

Norwegian reference values for the Short-Form Health Survey 36: development over time.

Jacobsen EL, Bye A, Aass N, Fosså SD, Grotmol KS, Kaasa S, Loge JH, Moum T, Hjermstad MJ.

Qual Life Res. 2018 May;27(5):1201-1212. doi: 10.1007/s11136-017-1684-4. Epub 2017 Aug 14. Erratum in: Qual Life Res. 2017 Nov 21;:.

32.

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Bruland ØS, Petrenciuc O, Staudacher K, Li R, Nilsson S.

Eur Urol. 2017 Jul 10. pii: S0302-2838(17)30516-X. doi: 10.1016/j.eururo.2017.06.021. [Epub ahead of print]

33.

A controlled study of the influence of comorbidity on activities of daily living in elderly cancer survivors (the HUNT-3 survey).

Grov EK, Fosså SD, Dahl AA.

J Geriatr Oncol. 2017 Sep;8(5):328-335. doi: 10.1016/j.jgo.2017.05.007. Epub 2017 Jun 16.

PMID:
28629695
34.

Feasibility of a physical activity intervention during and shortly after chemotherapy for testicular cancer.

Thorsen L, Kirkegaard C, Loge JH, Kiserud CE, Johansen ML, Gjerset GM, Edvardsen E, Hamre H, Ikdahl T, Fosså SD.

BMC Res Notes. 2017 Jun 15;10(1):214. doi: 10.1186/s13104-017-2531-y.

35.

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.

Dolan ME, El Charif O, Wheeler HE, Gamazon ER, Ardeshir-Rouhani-Fard S, Monahan P, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kim J, Fossa SD, Hertz DL, Mushiroda T, Kubo M, Einhorn LH, Cox NJ, Travis LB; Platinum Study Group.

Clin Cancer Res. 2017 Oct 1;23(19):5757-5768. doi: 10.1158/1078-0432.CCR-16-3224. Epub 2017 Jun 13.

36.

Modern treatment of metastatic prostate cancer.

Holm HV, Dahl AA, Klepp OH, Fosså SD.

Tidsskr Nor Laegeforen. 2017 Jun 6;137(11):803-805. doi: 10.4045/tidsskr.16.0265. eCollection 2017 Jun. Review. English, Norwegian.

37.

International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer.

van Leeuwen M, Kieffer JM, Efficace F, Fosså SD, Bolla M, Collette L, Colombel M, De Giorgi U, Holzner B, van de Poll-Franse LV, van Poppel H, White J, de Wit R, Osanto S, Aaronson NK; European Organisation for Research and Treatment of Cancer Quality of Life Group; Genito-Urinary Cancers Group and Radiation Oncology Group; and the NCRN Testis Clinical Studies Group.

Health Qual Life Outcomes. 2017 May 11;15(1):97. doi: 10.1186/s12955-017-0670-4.

38.

Pre- and post-prostatectomy variables associated with pelvic post-operative radiotherapy in prostate cancer patients: a national registry-based study.

Vatne K, Stensvold A, Myklebust TÅ, Møller B, Svindland A, Kvåle R, Fosså SD.

Acta Oncol. 2017 Oct;56(10):1295-1301. doi: 10.1080/0284186X.2017.1314006. Epub 2017 Apr 19.

PMID:
28422584
39.

Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.

Fung C, Sesso HD, Williams AM, Kerns SL, Monahan P, Abu Zaid M, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Kollmannsberger CK, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Lipshultz SE, Einhorn LH, Fossa SD, Travis LB; Platinum Study Group.

J Clin Oncol. 2017 Apr 10;35(11):1211-1222. doi: 10.1200/JCO.2016.70.3108. Epub 2017 Feb 27.

40.

Experiences with late effects-related care and preferences for long-term follow-up care among adult survivors of childhood lymphoma.

Lie HC, Mellblom AV, Brekke M, Finset A, Fosså SD, Kiserud CE, Ruud E, Loge JH.

Support Care Cancer. 2017 Aug;25(8):2445-2454. doi: 10.1007/s00520-017-3651-6. Epub 2017 Feb 24.

PMID:
28236146
41.

Re: Behandling eller aktiv monitorering ved prostatakreft?

Fosså SD.

Tidsskr Nor Laegeforen. 2017 Feb 21;137(4):259-260. doi: 10.4045/tidsskr.17.0046. eCollection 2017 Feb. Norwegian. No abstract available.

PMID:
28225224
Free Article
42.

Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.

Skalleberg J, Solheim O, Fosså SD, Småstuen MC, Osnes T, Gundersen POM, Bunne M.

Gynecol Oncol. 2017 Apr;145(1):148-153. doi: 10.1016/j.ygyno.2017.02.006. Epub 2017 Feb 12.

PMID:
28202195
43.

Stomach Cancer Following Hodgkin Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a Focus on Radiation Effects.

Gilbert ES, Curtis RE, Hauptmann M, Kleinerman RA, Lynch CF, Stovall M, Smith SA, Weathers R, Andersson M, Dores GM, Fraumeni JF Jr, Fossa SD, Hall P, Hodgson DC, Holowaty EJ, Joensuu H, Johannesen TB, Langmark F, Kaijser M, Pukkala E, Rajaraman P, Storm HH, Vaalavirta L, van den Belt-Dusebout AW, Aleman BM, Travis LB, Morton LM, van Leeuwen FE.

Radiat Res. 2017 Feb;187(2):186-195. doi: 10.1667/RR14453.1. Epub 2017 Jan 24.

44.

Bone mineral density is close to normal for age in long-term lymphoma survivors treated with high-dose therapy with autologous stem cell transplantation.

Seland M, Smeland KB, Bjøro T, Falk RS, Fosså SD, Gjesdal CG, Godang K, Holte H, Svartberg J, Syversen U, Bollerslev J, Kiserud CE.

Acta Oncol. 2017 Apr;56(4):590-598. doi: 10.1080/0284186X.2016.1267870. Epub 2017 Jan 12.

PMID:
28077016
45.

Perceived needs for different components in a rehabilitation program among cancer survivors with chronic fatigue compared to survivors without chronic fatigue.

Gjerset GM, Loge JH, Kiserud CE, Fosså SD, Gudbergsson SB, Oldervoll LM, Wisløff T, Thorsen L.

Acta Oncol. 2017 Feb;56(2):245-253. doi: 10.1080/0284186X.2016.1266091. Epub 2017 Jan 11.

PMID:
28075207
46.

Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity.

Wheeler HE, Gamazon ER, Frisina RD, Perez-Cervantes C, El Charif O, Mapes B, Fossa SD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kollmannsberger C, Kim J, Mushiroda T, Kubo M, Ardeshir-Rouhani-Fard S, Einhorn LH, Cox NJ, Dolan ME, Travis LB.

Clin Cancer Res. 2017 Jul 1;23(13):3325-3333. doi: 10.1158/1078-0432.CCR-16-2809. Epub 2016 Dec 30.

47.

Prescriptions of Antidepressants to Survivors of Cancer in Childhood, Adolescence, and Young Adulthood: A Population-Based Study.

Johannsdottir IM, Karlstad Ø, Loge JH, Fosså SD, Kiserud C, Skurtveit S.

J Adolesc Young Adult Oncol. 2017 Mar;6(1):120-126. doi: 10.1089/jayao.2016.0041. Epub 2016 Nov 14.

PMID:
27841952
48.

Increased pancreatic cancer risk following radiotherapy for testicular cancer.

Hauptmann M, Børge Johannesen T, Gilbert ES, Stovall M, van Leeuwen FE, Rajaraman P, Smith SA, Weathers RE, Aleman BM, Andersson M, Curtis RE, Dores GM, Fraumeni JF Jr, Hall P, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Lynch CF, Pukkala E, Storm HH, Vaalavirta L, van den Belt-Dusebout AW, Morton LM, Fossa SD, Travis LB.

Br J Cancer. 2016 Sep 27;115(7):901-8. doi: 10.1038/bjc.2016.272. Epub 2016 Sep 6.

49.

Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.

Hjelle LV, Bremnes RM, Gundersen POM, Sprauten M, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Oldenburg J, Haugnes HS.

Urol Oncol. 2016 Nov;34(11):487.e13-487.e20. doi: 10.1016/j.urolonc.2016.06.012. Epub 2016 Aug 11.

PMID:
27523611
50.

Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA.

Paur I, Lilleby W, Bøhn SK, Hulander E, Klein W, Vlatkovic L, Axcrona K, Bolstad N, Bjøro T, Laake P, Taskén KA, Svindland A, Eri LM, Brennhovd B, Carlsen MH, Fosså SD, Smeland SS, Karlsen AS, Blomhoff R.

Clin Nutr. 2017 Jun;36(3):672-679. doi: 10.1016/j.clnu.2016.06.014. Epub 2016 Jun 30.

Supplemental Content

Loading ...
Support Center